Digestive Care, Inc. (DCI) and its marketing partner to support the U.S. cystic fibrosis community, Chiesi, today announced U.S. Food and Drug Administration (FDA) approval of PERTZYE® (pancrelipase) in a 24,000 USP lipase units capsule. The newly available dosing strength may allow for consumption of fewer capsules to reach the needed weight-based dose. More: http://mwne.ws/2tyAapF
Client & Alumni News
Digestive Care Announces FDA Approval of Medication to Treat Pancreatic Insufficiency Due to Cystic Fibrosis
The Ben Franklin Technology Partners is an initiative of the Pennsylvania Department of Community and Economic Development and is funded by the Ben Franklin Technology Development Authority.